Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population-Reference-Cited by-同舟云学术

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population

Published:2022-05-24 Issue:2 Volume:187 Page:263-265
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Mastorino Luca¹^ORCID,Roccuzzo Gabriele¹^ORCID,Dapavo Paolo¹,Siliquini Niccolò¹^ORCID,Avallone Gianluca¹^ORCID,Rubatto Marco¹,Merli Martina¹,Agostini Andrea¹,Ribero Simone¹^ORCID,Quaglino Pietro¹^ORCID

Affiliation:

1. Department of Medical Sciences, Dermatologic Clinic University of Turin Turin Italy

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.21048

Reference8 articles.

1. Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data of a real‐life 16‐week retrospective study

2. Secukinumab in multi-failure psoriatic patients: the last hope?

3. Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience

4. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

5. The successful treatment with ixekizumab in a multi-failure psoriasis patient

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulation of the skin and gut microbiome by psoriasis treatment: a comprehensive systematic review;Archives of Dermatological Research;2024-06-08

2. Multi‐treatment resistance to biological treatment in patients with psoriasis: Definitions and implications;Journal of the European Academy of Dermatology and Venereology;2024-05-31

3. Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study;International Journal of Dermatology;2024-04-07

4. Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort;International Journal of Dermatology;2024-01-05

5. Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-01